$6.62
0.18[2.80%]
At close: Apr 26
$6.62
0[0.00%]
After Hours: 7:55PM EDT
ADMA Biologics
(NASDAQ:ADMA)ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions
ADMA Biologics Inc has a consensus price target of $7.88, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Mizuho, and Cantor Fitzgerald on March 26, 2024, March 1, 2024, and February 29, 2024. With an average price target of $8.5 between HC Wainwright & Co., Mizuho, and Cantor Fitzgerald, there's an implied 28.40% upside for ADMA Biologics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Mizuho
Cantor Fitzgerald
Raymond James
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ADMA Biologics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/26/2024 | ADMA | Buy Now | ADMA Biologics | $6.62 | 13.29% | HC Wainwright & Co. | Raghuram Selvaraju | $6 → $7.5 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | ADMA | Buy Now | ADMA Biologics | $6.62 | 51.06% | Mizuho | Anthony Petrone | $9 → $10 | Maintains | Buy | Get Alert |
| 02/29/2024 | ADMA | Buy Now | ADMA Biologics | $6.62 | 20.85% | Cantor Fitzgerald | Kristen Kluska | $6.5 → $8 | Maintains | Overweight | Get Alert |
| 02/29/2024 | ADMA | Buy Now | ADMA Biologics | $6.62 | -9.37% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | Buy → Buy | Get Alert |
| 01/22/2024 | ADMA | Buy Now | ADMA Biologics | $6.62 | 35.95% | Mizuho | Anthony Petrone | $7 → $9 | Maintains | Buy | Get Alert |
| 01/09/2024 | ADMA | Buy Now | ADMA Biologics | $6.62 | -9.37% | HC Wainwright & Co. | Raghuram Selvaraju | $5 → $6 | Maintains | Buy | Get Alert |
| 12/19/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -9.37% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 11/17/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -24.47% | HC Wainwright & Co. | Raghuram Selvaraju | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -9.37% | Cantor Fitzgerald | Kristen Kluska | $5 → $6 | Maintains | Overweight | Get Alert |
| 08/10/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -9.37% | Raymond James | Elliot Wilbur | $5 → $6 | Maintains | Strong Buy | Get Alert |
| 08/10/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -24.47% | HC Wainwright & Co. | Raghuram Selvaraju | $4.5 → $5 | Maintains | Buy | Get Alert |
| 03/27/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -32.02% | HC Wainwright & Co. | Raghuram Selvaraju | → $4.5 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -32.02% | HC Wainwright & Co. | Raghuram Selvaraju | → $4.5 | Reiterates | → Buy | Get Alert |
| 01/03/2023 | ADMA | Buy Now | ADMA Biologics | $6.62 | -32.02% | HC Wainwright & Co. | Raghuram Selvaraju | $4 → $4.5 | Maintains | Buy | Get Alert |
| 11/10/2022 | ADMA | Buy Now | ADMA Biologics | $6.62 | -9.37% | Mizuho | Anthony Petrone | $5 → $6 | Maintains | Buy | Get Alert |
| 10/13/2022 | ADMA | Buy Now | ADMA Biologics | $6.62 | -24.47% | Mizuho | Anthony Petrone | → $5 | Initiates | → Buy | Get Alert |
| 07/25/2022 | ADMA | Buy Now | ADMA Biologics | $6.62 | -39.58% | HC Wainwright & Co. | Raghuram Selvaraju | $6 → $4 | Maintains | Buy | Get Alert |
| 11/11/2021 | ADMA | Buy Now | ADMA Biologics | $6.62 | -24.47% | Raymond James | Elliot Wilbur | — | Upgrade | Outperform → Strong Buy | Get Alert |
| 11/09/2021 | ADMA | Buy Now | ADMA Biologics | $6.62 | -32.02% | Cantor Fitzgerald | Kristen Kluska | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for ADMA Biologics (ADMA)?
The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by HC Wainwright & Co. on March 26, 2024. The analyst firm set a price target for $7.50 expecting ADMA to rise to within 12 months (a possible 13.29% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADMA Biologics (ADMA)?
The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by HC Wainwright & Co., and ADMA Biologics reiterated their buy rating.
When was the last upgrade for ADMA Biologics (ADMA)?
The last upgrade for ADMA Biologics Inc happened on November 11, 2021 when Raymond James raised their price target to $5. Raymond James previously had an outperform for ADMA Biologics Inc.
When was the last downgrade for ADMA Biologics (ADMA)?
There is no last downgrade for ADMA Biologics.
When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on March 26, 2024 so you should expect the next rating to be made available sometime around March 26, 2025.
Is the Analyst Rating ADMA Biologics (ADMA) correct?
While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a reiterated with a price target of $6.00 to $7.50. The current price ADMA Biologics (ADMA) is trading at is $6.62, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.